Drug Trial Radar · NCT04326829
QL1604 Monotherapy for dMMR or MSI-H Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Dec 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
86
Planned (sponsor's estimate)
Start
Jul 8, 2020
Primary completion
Dec 2022
Study completion Jul 2023
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 30, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, patients with previously-treated locally-advanced or metastatic mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal carcinoma (CRC) and other solid tumors will be treated with QL1604 monotherapy.
Conditions
- Advanced Malignant Tumor
Interventions
QL1604Drug
QL1604, IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORRTime frame: up to 2 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Fudan University Cancer Hospital
Shanghai, Shanghai Municipality, China · Recruiting
West China Hospital, Sichuan University
Chengdu, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.